share_log

Grail | 8-K: Current report

Grail | 8-K: Current report

Grail | 8-K:重大事件
美股SEC公告 ·  2024/10/22 21:13

牛牛AI助理已提取核心訊息

Grail announced the appointment of Sarah Krevans to its Board of Directors effective October 21, 2024. Krevans will serve as a Class II director until 2026 and join the Board's Audit, Compensation, and Nominating and Governance committees. The appointment expands the Board to five directors, with four being independent.As the former President and CEO of Sutter Health from 2016 to 2022, Krevans led an integrated network of 14,000 clinicians and 24 hospitals, advancing clinical programs and digital health initiatives. Her compensation includes a $50,000 annual cash retainer for Board service, additional committee retainers, and an initial grant of 31,055 restricted stock units vesting over three years.Krevans brings extensive healthcare leadership experience, having previously served as COO at Sutter Health and held executive positions at Kaiser Permanente. She holds master's degrees from UC Berkeley and has been recognized among Modern Healthcare's "Top 25 Women Leaders" and "100 Most Influential People in Healthcare."
Grail announced the appointment of Sarah Krevans to its Board of Directors effective October 21, 2024. Krevans will serve as a Class II director until 2026 and join the Board's Audit, Compensation, and Nominating and Governance committees. The appointment expands the Board to five directors, with four being independent.As the former President and CEO of Sutter Health from 2016 to 2022, Krevans led an integrated network of 14,000 clinicians and 24 hospitals, advancing clinical programs and digital health initiatives. Her compensation includes a $50,000 annual cash retainer for Board service, additional committee retainers, and an initial grant of 31,055 restricted stock units vesting over three years.Krevans brings extensive healthcare leadership experience, having previously served as COO at Sutter Health and held executive positions at Kaiser Permanente. She holds master's degrees from UC Berkeley and has been recognized among Modern Healthcare's "Top 25 Women Leaders" and "100 Most Influential People in Healthcare."
Grail宣佈任命Sarah Krevans爲其董事會成員,任命自2024年10月21日起生效。Krevans將擔任二級董事,任期至2026年,並加入董事會的審計、薪酬以及提名和治理委員會。此次任命使董事會擴展至五名董事,其中四名爲獨立董事。作爲2016年至2022年Sutter Health的前任總裁兼首席執行官,Krevans領導着一個由14,000名臨牀醫生和24家醫院組成的綜合網絡,推動臨牀項目和互聯網醫療倡議。她的薪酬包括董事會服務的每年50,000美元現金保留金,額外的委員會保留金,以及初始授予31,055個限制性股票單位,這些股票將在三年內逐步解禁。Krevans擁有豐富的醫療領導經驗,曾擔任Sutter Health的首席運營官,並在凱澤永久擔任過高管職位。她擁有加州大學伯克利分校的碩士學位,並被現代醫療評選爲「25位傑出女性領導者」和「100位最具影響力的醫療人物」之一。
Grail宣佈任命Sarah Krevans爲其董事會成員,任命自2024年10月21日起生效。Krevans將擔任二級董事,任期至2026年,並加入董事會的審計、薪酬以及提名和治理委員會。此次任命使董事會擴展至五名董事,其中四名爲獨立董事。作爲2016年至2022年Sutter Health的前任總裁兼首席執行官,Krevans領導着一個由14,000名臨牀醫生和24家醫院組成的綜合網絡,推動臨牀項目和互聯網醫療倡議。她的薪酬包括董事會服務的每年50,000美元現金保留金,額外的委員會保留金,以及初始授予31,055個限制性股票單位,這些股票將在三年內逐步解禁。Krevans擁有豐富的醫療領導經驗,曾擔任Sutter Health的首席運營官,並在凱澤永久擔任過高管職位。她擁有加州大學伯克利分校的碩士學位,並被現代醫療評選爲「25位傑出女性領導者」和「100位最具影響力的醫療人物」之一。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 243

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。